Abstract:Introduction: Accumulating evidence indicates that b romodomain and e xtra- t erminal domain (BET) proteins play a pivotal role in the transcriptional regulation of the inflammatory response, and consequently, BET inhibition has emerged as a promising novel therapeutic strategy to reduce inflammation linked to many diseases, including ischemic brain injury. dBET1 is the first BET-targeted proteolysis-targeting chimera (PROTAC) that induces a rapid and efficient deletion of BET proteins in vivo . Hypothesis: In this study, we hypothesized that dBET1 protects against brain damage and neurological deficits in a transient cerebral ischemia mouse model through the regulation of the inflammatory process. Methods: Adult C57BL/6 WT mice were subjected to transient cerebral ischemia surgery (tMCAO) and were administered intraperitoneally with dBET1 (30 mg/kg) or vehicle at 4 and 24 hours after the stroke onset. Infarct volume, neurological deficits, blood-brain barrier integrity, and several inflammatory mediators were examined 48h after tMCAO. Results: The expression level of the BET protein, BRD4, in the cerebral cortex was remarkably lower in the dBET1-treated animals compared to the controls. dBET1 significantly reduced infarct volume (56.2±7.9%, P≤0.01, n=13-14) and improved the neurological performance in the open field test, vertical grid test, and neurological deficit scoring (P≤0.05, n=19-20). In dBET1-treated mice, in both ischemic striatum and cerebral cortex, the inflammation-associated reactive gliosis in astrocytes and microglia was significantly attenuated (P≤0.05, n=6), along with a reduction in stroke-mediated blood-brain barrier damage and neutrophil infiltration. Mechanistically, dBET1 produced a dramatic decrease in the expression levels of pro-inflammatory mediators, while it enhanced levels of anti-inflammatory mediators (P≤0.05, n=6). Conclusion: Overall, this study provides direct in vivo evidence that BET protein degradation with dBET1 suppresses neuroinflammation and leads to anatomical and functional protection against ischemic brain damage. Blocking BET proteins is a promising new strategy to reduce neuroinflammation and eventually improve functional outcomes in stroke.

Bromodomain Protein Inhibition Protects β-Cells from Cytokine-Induced Death and Dysfunction via Antagonism of NF-κB Pathway

2036-P: I-BET 762 Inhibits Inflammation-Induced Pancreatic Beta-Cell Apoptosis by Controlling Inflammatory Pathways

BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic β-Cell

BET Bromodomain Inhibition Suppresses Human T Cell Function

Bax Inhibitor-1 preserves pancreatic β-cell proteostasis by limiting proinsulin misfolding and programmed cell death

Human Expandable Pancreatic Progenitor–derived Β Cells Ameliorate Diabetes

Exploring Transcriptional Regulation of Beta Cell SASP by Brd4-Associated Proteins and Cell Cycle Control Protein p21

Inhibition of TBK1/IKKε Promotes Regeneration of Pancreatic β-cells

Beta cell specific cannabinoid 1 receptor deletion counteracts progression to hyperglycemia in non-obese diabetic mice

Neuropeptide Y1 receptor antagonism protects β-cells and improves glycemic control in type 2 diabetes

Bet N-Terminal Bromodomain Inhibition Selectively Blocks Th17 Cell Differentiation And Ameliorates Colitis In Mice

Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation

TBK1 regulates regeneration of pancreatic β-cells

Mitophagy Protects Beta Cells from Inflammatory Damage in Diabetes

A BET Protein Inhibitor Targeting Mononuclear Myeloid Cells Affects Specific Inflammatory Mediators and Pathways in Crohn's Disease

Glycolysis Inhibition Induces Functional and Metabolic Exhaustion of CD4+ T Cells in Type 1 Diabetes

Inhibition of PHLPP1/2 phosphatases rescues pancreatic β-cells in diabetes

Abstract 164: Bet Protein Degradation With The Proteolysis-targeting Chimera, Dbet1, Ameliorates Brain Damage And Neurological Deficits After Transient Cerebral Ischemia

Apabetalone, a BET protein inhibitor, inhibits kidney damage in diabetes by preventing pyroptosis via modulating the P300/H3K27ac/PLK1 axis

Jq 1, A Selective Bromodomain Inhibitor, Decreased the Expression of the Tolerogenic Molecule Pdl1 in Antigen-Presenting Cells (apcs) and Restores the Responsiveness of Anergic Cd4+T Cells

Histone Deacetylase Inhibitors Prevent Cytokine-Induced β Cell Dysfunction Through Restoration of Stromal Interaction Molecule 1 Expression and Activation of Store-Operated Calcium Entry